Dat	te:Mar. 15 th , 2021					
	ur Name: Dingrong Zhan					
Ma	Manuscript Title: Long ncRNA MALAT1 promotes cell proliferation, migration, and invasion in prostate cancer via					
	onging miR-145	•				
	nuscript number (if known)): TAU-20-1526				
						
rela par to t rela	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest,	manuscript. "Related" mea e affected by the content on necessarily indicate a bias. it is preferable that you do				
	e following questions apply inuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>			
to to to me	the epidemiology of hypertodication, even if that medic	ension, you should declare cation is not mentioned in to poort for the work reporte	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other iten			
		Name all entities with	Specifications/Comments			
		whom you have this	(e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as	,			
		needed)				
		Time frame: Since the initia	planning of the work			
. 1	All support for the present	X None				
L	manuscript (e.g., funding,	^_None				
	provision of study materials,					
	medical writing, article					
	processing charges, etc.)					
	No time limit for this item.					
		Time from a most	26 months			
,	Crants or contracts from	Time frame: past	50 months			
<u>-</u>	Grants or contracts from any entity (if not indicated	XNone				
	in item #1 above).					
3	Royalties or licenses	X None				
	noyalties of neerises					
1	Consulting fees	X None				

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ase summarize the above co	onflict of interest in the fol	lowing box:
Ple	ase place an "X" next to the	e following statement to in	dicate your agreement:

Da	ite:Mar. 15 th , 2021	_		
Yo	ur Name: Cheng Fang			
Ma	anuscript Title: Long n	cRNA MALAT1 promotes co	ell proliferation, migration, and invasion in prostate ca	ncer via
sp	onging miR-145			
Ma	anuscript number (if known)	:TAU-20-1526		
rel pa to rel Th ma	rties whose interests may be transparency and does not a lationship/activity/interest, e following questions apply anuscript only. e author's relationships/activite epidemiology of hypertedication, even if that medications	manuscript. "Related" means affected by the content of the author's relationship ivities/interests should be the content of th	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript perta all relationships with manufacturers of antihypertensi	ains ive
	e time frame for disclosure i	•	·	ŕ
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initial	planning of the work	
	All support for the present	X None		
_	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
	No time initial toli tima item.			
		Time frame: past	36 months	
)	Grants or contracts from	X None		
	any entity (if not indicated			
	in item #1 above).			
}	Royalties or licenses	X None		
	Noyulties of ficerises			
1	Consulting fees	XNone		
	, -	,	1	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XNone	
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ease summarize the above connection	onflict of interest in the fo	lowing box:
Ple	ase place an "X" next to the	following statement to in	dicate vour agreement:

You Ma specific Main relation relation relation relations.	onging miR-145 anuscript number (if known) the interest of transparency ated to the content of your rties whose interests may be transparency and does not a	cRNA MALAT1 promotes ce :TAU-20-1526, we ask you to disclose all manuscript. "Related" mea e affected by the content o necessarily indicate a bias. it is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a	via
to me	the epidemiology of hyperte edication, even if that medic	ension, you should declare ation is not mentioned in toport for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items	•
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: past	36 months	
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	XNone XNone		
4	Consulting fees	X None		
7	i Consulting ICCS	I A INDIE	ı	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ase summarize the above co	onflict of interest in the fol	lowing box:
Ple	ase place an "X" next to the	e following statement to in	dicate your agreement:

Da	te:Mar. 15 th , 2021	_		
Yo	ur Name: Chunyuan Lu_	_		
Ma	anuscript Title: Long n	cRNA MALAT1 promotes	cell proliferation, migration, and invasion in prostate car	ncer via
spo	onging miR-145			
Ma	anuscript number (if known):TAU-20-1526		
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.	
	e following questions apply anuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to me	the epidemiology of hypertedication, even if that medic	ension, you should declare cation is not mentioned in pport for the work report	e defined broadly. For example, if your manuscript perta e all relationships with manufacturers of antihypertension the manuscript. ed in this manuscript without time limit. For all other ite	ve
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as	mstrution	
		needed)		
		Time frame: Since the initia	al planning of the work	
		Time trainer since the lines	ar planning of the work	
L	All support for the present	XNone		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame, nee	t 26 months	
	County on soul	Time frame: pas	t 50 months	
<u> </u>	Grants or contracts from	XNone		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	XNone		
	Consulting for	V. Name		
ŧ	Consulting fees	X None		

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XNone	
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ease summarize the above connection	onflict of interest in the fo	lowing box:
Ple	ase place an "X" next to the	following statement to in	dicate vour agreement:

Dat	te:Mar. 15 th , 2021					
	our Name: Jiaohong Huang					
	Manuscript Title: Long ncRNA MALAT1 promotes cell proliferation, migration, and invasion in prostate cancer via					
	onging miR-145	•				
	nuscript number (if known)):TAU-20-1526				
			relationships/activities/interests listed below that are			
	-	-	ans any relation with for-profit or not-for-profit third			
-	-	-	f the manuscript. Disclosure represents a commitment			
	_	-	If you are in doubt about whether to list a			
rela	ationship/activity/interest,	it is preferable that you do	so.			
		to the author's relationship	ps/activities/interests as they relate to the <u>current</u>			
<u>ma</u>	nuscript only.					
Th.		::	defined by a diversity. For a community if we were many and in a mantain	_		
		-	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive			
	dication, even if that medic	· •	•			
me	ulcation, even il that medic	ation is not mentioned in t	ine manuscript.			
In i	tem #1 helow report all su	nnort for the work renorted	d in this manuscript without time limit. For all other iten	16		
	time frame for disclosure i		u in this manuscript without time innit. For an other item	15,		
tile	tille frame for disclosure i	s the past 30 months.				
		Name all entities with	Specifications/Comments			
		whom you have this	(e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as				
		needed)				
		Time frame: Since the initial	planning of the work			
1	All support for the present	X None				
	manuscript (e.g., funding,					
	provision of study materials,					
	medical writing, article					
	processing charges, etc.)					
	No time limit for this item.					
		Time frame: past	36 months			
2	Grants or contracts from	XNone				
	any entity (if not indicated					
	in item #1 above).					
3	Royalties or licenses	XNone				
4	Consulting fees	X None				

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XNone	
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ease summarize the above connection	onflict of interest in the fo	lowing box:
Ple	ase place an "X" next to the	following statement to in	dicate vour agreement:

Da	te:Mar. 15 , 2021	_		
Yo	ur Name: Jiancheng Pan			
Ma	nuscript Title: Long n	cRNA MALAT1 promotes	cell proliferation, migration, and invasion in prostate cance	r via
spo	onging miR-145			
Ma	nuscript number (if known)):TAU-20-1526		
rel pa to rel	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest,	manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you d		
	e following questions apply inuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to me	the epidemiology of hyperto dication, even if that medic	ension, you should declare cation is not mentioned in pport for the work reporte	e defined broadly. For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items	÷,
		Name all entities with	Specifications/Comments	
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your institution)	
		needed) Time frame: Since the initia	al planning of the work	
			ar pranting of the front	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: pas	t 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		
4	Consulting fees	X None		

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XNone	
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ease summarize the above connection	onflict of interest in the fo	lowing box:
Ple	ase place an "X" next to the	following statement to in	dicate vour agreement:

Da	te:Mar. 15 th , 2021	_		
Yo	ur Name: Zhizhao Yang_	_		
Ma	anuscript Title: Long n	cRNA MALAT1 promotes o	ell proliferation, migration, and invasion in prostate cancer	via
sp	onging miR-145			
Ma	anuscript number (if known)):TAU-20-1526		
rel pa to rel	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest,	manuscript. "Related" me e affected by the content on necessarily indicate a bias. it is preferable that you do		
	e following questions apply anuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to me	the epidemiology of hypertoedication, even if that medic	ension, you should declare cation is not mentioned in pport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items	,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as	,	
		needed)		
		Time frame: Since the initia	l planning of the work	
1	All support for the present	X None		
_	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: past	26 months	
2	Grants or contracts from			
۷.	any entity (if not indicated	XNone		
	in item #1 above).			
3	Royalties or licenses	X None		
,				
	novaleies of meetises			
	Troyalties of lifetimes			

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XNone	
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ease summarize the above connection	onflict of interest in the fo	lowing box:
Ple	ase place an "X" next to the	following statement to in	dicate vour agreement:

Dat	e:Mar. 15 th , 2021	_		
You	r Name: Enli Liang			
Ma	nuscript Title: Long n	cRNA MALAT1 promotes co	ell proliferation, migration, and invasion in prostate ca	ncer via
spo	nging miR-145			
Ma	nuscript number (if known)	:TAU-20-1526		
In the man	he interest of transparency ted to the content of your ties whose interests may be ransparency and does not itionship/activity/interest, following questions apply nuscript only.	r, we ask you to disclose all manuscript. "Related" mea e affected by the content onecessarily indicate a bias. it is preferable that you do to the author's relationship ivities/interests should be ension, you should declare	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the manuscript. Disclosure represents a commitment of the manuscript about whether to list a so. ps/activities/interests as they relate to the current of activities defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensity.	ains
	em #1 below, report all su time frame for disclosure i	-	d in this manuscript without time limit. For all other it	ems,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initial	planning of the work	
\Box	All support for the present	X None		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: past	36 months	
)	Grants or contracts from	X None		
-	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	X None		
	,			
	Consulting fees	XNone		

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XNone	
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ease summarize the above connection	onflict of interest in the fo	lowing box:
Ple	ase place an "X" next to the	following statement to in	dicate vour agreement:

Da	te:Mar. 15 , 2021	_		
Yo	ur Name: Zhifei Liu			
Ma	nuscript Title: Long n	cRNA MALAT1 promotes	cell proliferation, migration, and invasion in prostate can	cer via
spo	onging miR-145			
Ma	nuscript number (if known)):TAU-20-1526		
rela par to	ated to the content of your ties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.	
	e following questions apply nuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to me	the epidemiology of hypertodication, even if that medic	ension, you should declare cation is not mentioned in pport for the work reporte	e defined broadly. For example, if your manuscript pertain e all relationships with manufacturers of antihypertensiv the manuscript. ed in this manuscript without time limit. For all other ite	e
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as	mstrution)	
		needed)		
		Time frame: Since the initia	al planning of the work	
	All account for the consecut			
L	All support for the present manuscript (e.g., funding,	XNone		
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: pas	t 36 months	
<u>?</u>	Grants or contracts from	XNone		
	any entity (if not indicated			
	in item #1 above).	Y N		
5	Royalties or licenses	XNone		
1	Consulting fees	X None		

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XNone	
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ease summarize the above connection	onflict of interest in the fo	lowing box:
Ple	ase place an "X" next to the	following statement to in	dicate vour agreement:

You Ma spo Ma In the relation relation The	onging miR-145 anuscript number (if known) the interest of transparency ated to the content of your rties whose interests may be transparency and does not a tionship/activity/interest, e following questions apply	u cRNA MALAT1 promotes ce :TAU-20-1526 , we ask you to disclose all manuscript. "Related" mea e affected by the content o necessarily indicate a bias. it is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a	' via
The to me	the epidemiology of hyperte dication, even if that medic	ension, you should declare ation is not mentioned in to the propertion of the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items	وا
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: past	36 months	
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	XNone XNone		
4	Consulting fees	X None		
+ !	CONSUMING IEES	I A NUITE I	l l	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XNone	
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ease summarize the above connection	onflict of interest in the fo	lowing box:
Ple	ase place an "X" next to the	following statement to in	dicate vour agreement:

Da	nte:Mar. 15 th , 2021	_		
Yo	ur Name: Zhongcheng Xi	in		
M	anuscript Title: Long n	cRNA MALAT1 promotes c	ell proliferation, migration, and invasion in prostate cance	r via
sp	onging miR-145			
-	anuscript number (if known)):TAU-20-1526		
re pa to	lated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content on necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.	
	e following questions apply anuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to me	the epidemiology of hypertoedication, even if that medic	ension, you should declare cation is not mentioned in pport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. In this manuscript without time limit. For all other items	
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as	,	
		needed)		
		Time frame: Since the initia	l planning of the work	
1	All support for the present	X None		
1	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: past	36 months	
2	Grants or contracts from	XNone		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	XNone		
4	Consulting fees	X None		

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XNone	
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ease summarize the above connection	onflict of interest in the fo	lowing box:
Ple	ase place an "X" next to the	following statement to in	dicate vour agreement:

You Ma spo Ma In t	onging miR-145 nuscript number (if known) the interest of transparency ated to the content of your	cRNA MALAT1 promotes ce :TAU-20-1526 , we ask you to disclose all manuscript. "Related" mea	ell proliferation, migration, and invasion in prostate cance relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment	er via
to	-	necessarily indicate a bias.	If you are in doubt about whether to list a	
	e following questions apply nuscript only.	to the author's relationship	ps/activities/interests as they relate to the <u>current</u>	
to i	the epidemiology of hypertedication, even if that medic	ension, you should declare ation is not mentioned in t pport for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other item	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: past	36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		
4	Consulting fees	X None		

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XNone	
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ease summarize the above connection	onflict of interest in the fo	lowing box:
Ple	ase place an "X" next to the	following statement to in	dicate vour agreement:

Dat	te:Mar. 15 th , 2021			
	ur Name:Qiliang Cai	_		
		cRNA MALAT1 promotes c	ell proliferation, migration, and invasion in prostate cancer v	ia
	onging miR-145	•	, , , , , , , , , , , , , , , , , , , ,	
	nuscript number (if known)):TAU-20-1526		
In t rela par to t rela The to t me	the interest of transparency ated to the content of your ties whose interests may be transparency and does not ationship/activity/interest, a following questions apply nuscript only. The author's relationships/activity epidemiology of hypertodication, even if that medication, even if that medication.	we ask you to disclose all manuscript. "Related" me e affected by the content on necessarily indicate a bias. it is preferable that you do to the author's relationship ivities/interests should be ension, you should declare cation is not mentioned in the same as the same	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so. ps/activities/interests as they relate to the current defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.	
	tem #1 below, report all su time frame for disclosure i	• •	d in this manuscript without time limit. For all other items,	
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initia	l planning of the work	
. [All support for the present	X None		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: past	36 months	
2	Grants or contracts from	XNone		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	XNone		
	Consulting fees	X None		

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XNone	
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
	ease summarize the above connection	onflict of interest in the fo	lowing box:
Ple	ease place an "X" next to the	following statement to in	dicate vour agreement: